Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dom.12878 http://scihub22266oqcxt.onion/10.1111/dom.12878 C5484336!5484336 !28094466     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28094466 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Diabetes+Obes+Metab 2017 ; 19 (6 ): 800-808 Nephropedia Template TP {{tp|p=28094466 |t=2017. Effects of ?-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease |pdf=|usr=}}{{28094466 }} gab.com Text Effects of -blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease JO: Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=28094466 #FOAvip AIMS: To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD). MATERIALS AND METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of ?-blockers on all-cause mortality in 2244 patients with type 2 diabetes who had stable CHD with and without a history of myocardial infarction (MI)/heart failure with reduced left ventricular ejection fraction (HFrEF). RESULTS: All-cause mortality in patients with MI/HFrEF was significantly lower in those receiving ?-blockers than in those not receiving ?-blockers (adjusted hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.37-0.98; P ?=?.04), whereas that in patients without MI/HFrEF did not significantly differ (adjusted HR 0.91, 95% CI 0.76-1.32; P ?=?.64). Among patients with MI/HFrEF, all-cause mortality in those who received intensive medical therapy alone for CHD was significantly lower in those on ?-blockers than in those not on ?-blockers (adjusted HR 0.45, 95% CI 0.23-0.88; P ?=?.02); however, mortality in patients who received early revascularization for CHD was not significantly lower in those on ?-blockers (adjusted HR 0.81, 95% CI 0.40-1.65; P ?=?.57). The risk of major cardiovascular events in patients without MI/HFrEF was not significantly different between those on and those not on ?-blocker treatment. CONCLUSIONS: In patients with diabetes and CHD, the use of ?-blockers was effective in reducing all-cause mortality in those with MI/HFrEF but not in those without MI/HFrEF. Twit Text FOAVip Effects of -blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease ????Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=28094466 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28094466 #FOAvip English Wikipedia <ref>{{Cite pmid|28094466 }}</ref> Effects of ?-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease #MMPMID28094466 Tsujimoto T ; Sugiyama T ; Kajio H Diabetes Obes Metab 2017[Jun]; 19 (6 ): 800-808 PMID28094466 show ga AIMS: To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD). MATERIALS AND METHODS: Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of ?-blockers on all-cause mortality in 2244 patients with type 2 diabetes who had stable CHD with and without a history of myocardial infarction (MI)/heart failure with reduced left ventricular ejection fraction (HFrEF). RESULTS: All-cause mortality in patients with MI/HFrEF was significantly lower in those receiving ?-blockers than in those not receiving ?-blockers (adjusted hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.37-0.98; P ?=?.04), whereas that in patients without MI/HFrEF did not significantly differ (adjusted HR 0.91, 95% CI 0.76-1.32; P ?=?.64). Among patients with MI/HFrEF, all-cause mortality in those who received intensive medical therapy alone for CHD was significantly lower in those on ?-blockers than in those not on ?-blockers (adjusted HR 0.45, 95% CI 0.23-0.88; P ?=?.02); however, mortality in patients who received early revascularization for CHD was not significantly lower in those on ?-blockers (adjusted HR 0.81, 95% CI 0.40-1.65; P ?=?.57). The risk of major cardiovascular events in patients without MI/HFrEF was not significantly different between those on and those not on ?-blocker treatment. CONCLUSIONS: In patients with diabetes and CHD, the use of ?-blockers was effective in reducing all-cause mortality in those with MI/HFrEF but not in those without MI/HFrEF. |Adrenergic beta-Antagonists/*therapeutic use [MESH] |Aged [MESH] |Cause of Death [MESH] |Coronary Disease/drug therapy/etiology/*mortality [MESH] |Diabetes Mellitus, Type 2/complications/*mortality [MESH] |Female [MESH] |Heart Failure/drug therapy/etiology/mortality [MESH] |Humans [MESH] |Male [MESH] |Middle Aged [MESH] |Myocardial Infarction/drug therapy/etiology/mortality [MESH] |Proportional Hazards Models [MESH] |Stroke Volume/drug effects [MESH] |Treatment Outcome [MESH]Effects of ?-blockers on all-cause mortality in patients with type 2 d(epmc).pdf DeepDyve Pubget Overpricing